Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine

Amini-Bavil-Olyaee, Samad; Hosseini, Seyed Younes; Sabahi, Farzaneh; Alavian, Seyed Moayed

doi:10.1016/j.ijid.2007.05.001

Cited by 22 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rtA181T change has been reported to occur in the absence of rtM204I/V and is considered a primary resistance mutation (19, 20). In this study we found that L180M 3.37% (11), M204I 2.76% (9), and M204V 1.23% (4) were more common than had been reported previously in Iran (21, 22). Our results fall between the extremes reported by other studies around the world (7-12, 23).…”

Section: Discussionsupporting

confidence: 56%

Drug-Related Mutational Patterns in Hepatitis B Virus (HBV) Reverse Transcriptase Proteins From Iranian Treatment-Naïve Chronic HBV Patients

et al. 2013

View full text Add to dashboard Cite

BackgroundImmunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.ObjectivesThe aim of this study was to characterize the hepatitis B virus reverse transcriptase (RT) protein variations among Iranian chronic HBV carriers who did not receive any antiviral treatments.Materials and MethodsHepatitis B virus partial RT genes from 325 chronic in active carrier patients were amplified and directly sequenced. Nucleotide/amino acid substitutions were identified compared to the sequences obtained from the database.ResultsAll strains belonging to genotype D.365 amino-acid substitutions were found. Mutations related to lamivudine, adefovir, telbivudine, and entecavir occurred in (YMDD) 4% (n = 13), (SVQ) 17.23% (n = 56), (M204I/V + L180M) 2.45% (n = 8) and (M204I) 2.76% (n = 9) of patients, respectively.ConclusionsRT mutants do occur naturally and could be found in HBV carriers who have never received antiviral therapy. However, mutations related to drug resistance in Iranian treatment-naïve chronic HBV patients were found to be higher than other studies published formerly. Chronic HBV patients should be monitored closely prior the commencement of therapy to achieve the best regimen option.

show abstract

Section: Discussionsupporting

confidence: 56%

Drug-Related Mutational Patterns in Hepatitis B Virus (HBV) Reverse Transcriptase Proteins From Iranian Treatment-Naïve Chronic HBV Patients

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Logistic regression analysis demonstrated that high pretreatment HBV-DNA levels are independent factors for the occurrence of YMDD mutations. These findings are in accordance with the results of other studies (Amini-Bavil-Olyaee et al, 2008). HBeAg status at baseline is recognized as an independent factor for YMDD mutations.…”

Section: Discussionsupporting

confidence: 93%

Detection of HBV Resistance to Lamivudine in Patients with Chronic Hepatitis B Using Zip Nucleic Acid Probes in Kerman, Southeast of Iran

Afshar¹,

Mollaie²

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

HBV infection is contagious and may be transmitted vertically or horizontally by blood products and body secretions. Over 50% of Iranian carriers have contracted the infection prenatally, making this the most likely route of transmission of HBV in Iran. This study assesses the resistance to Lamivudine in patients with chronic hepatitis B infection using a new ZNA probe Real Time PCR method. To evaluate the effectiveness of Lamivudine therapy for chronic hepatitis B infection, a study was conducted on 70 patients (63 men and 7women), who had received the drug first line. All patients were tested for the presence of HBsAg and HBeAg, the serum ALT level and the HBV DNA load before and after treatment. In all samples resistance to Lamivudine was tested with the ZNA Probe. Our results showed that ZNA Probe Real Time PCR method could detect wild type,YMDD, and its mutants, tyrosine-isoleucine-aspartate-aspartate and tyrosine-valine-aspartate-Aspartate. Among an estimated seventy patients with chronic hepatitis B infection, 18 (25.7%) were resistant to lamivudine. Only one patient was negative for presence of HBS-Ag (5.6%) and two patients were negative for HBe-Ag (11.1%). Real-time PCR with Zip nucleic acid probes is a sensitive, specific and rapid detection method for mutations in the YMDD motif, which will be essential for monitoring patients undergoing Lamivudine antiviral therapy.

show abstract

“…Many studies have shown that mutations occur spontaneously in YMDD motif of HBV RT region among untreated patients, although it has [12,13] reported no YMDD mutant (0%) among lamivudine-untreated patients, while Wang et al, [14] determined 31.7% for incidence of YMDD motif mutation. Also, Tan et al, reported that overall incidence of spontaneously occurring YMDD mutation in lamivudine-untreated patients was 12.21%.…”

Section: Discussionmentioning

confidence: 99%

“…Other studies have showed the prevalence of 0%-5.3% for YMDD mutant among Iranian lamivudine-untreated patients. [12,15] Also, two mutations (4.4%) at codon rt181 were found, including rtA181T and rtA181S. It has been investigated that amino acid changes at codon rt181 (rtA181T/V/S) confer resistance to adefovir and treatment failure.…”

Section: Discussionmentioning

confidence: 99%

Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran)

Hamidi-Fard

Makvandi

Samarbafzadeh

et al. 2013

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine

Abstract: The present study using two cost-effective methods showed that genotype D of HBV is dominant among Iranian HBV-infected subjects, and HBV lamivudine-resistant strains do not exist naturally among Iranian patients not treated with lamivudine.

Cited by 22 publications

References 27 publications

Drug-Related Mutational Patterns in Hepatitis B Virus (HBV) Reverse Transcriptase Proteins From Iranian Treatment-Naïve Chronic HBV Patients

Drug-Related Mutational Patterns in Hepatitis B Virus (HBV) Reverse Transcriptase Proteins From Iranian Treatment-Naïve Chronic HBV Patients

Detection of HBV Resistance to Lamivudine in Patients with Chronic Hepatitis B Using Zip Nucleic Acid Probes in Kerman, Southeast of Iran

Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran)

Contact Info

Product

Resources

About